Download Files:
TEI-9647
$550 – $2,850
Products Details
Product Description
– TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget’s disease[1][2][3].
Web ID
– HY-12398
Storage Temperature
– -20°C (Powder, protect from light, stored under nitrogen)
Shipping
– Blue Ice
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C27H38O4
References
– [1]Miura D, et al. Antagonistic action of novel 1α,25-dihydroxyvitamin D<sub>3</sub>-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1α,25-dihydroxyvitamin D<sub>3</sub>. J Biol Chem. 1999 Jun 4;274(23):16392-9.|[2]Kazuya Takenouchi, et al. Synthesis and structure-activity relationships of TEI-9647 derivatives as Vitamin D<sub>3</sub> antagonists. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):31-4.|[3]Seiichi Ishizuka, et al. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D<sub>3</sub> from pagetic bone marrow cells. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):331-4.
CAS Number
– 173388-20-0
Molecular Weight
– 426.59
Compound Purity
– 85.50
SMILES
– O=C1O[C@@H](C[C@H]([C@H]2CC[C@@]3([H])/C(CCC[C@]23C)=C/C=C4C([C@@H](O)C[C@H](O)C4)=C)C)CC1=C
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease; Inflammation/Immunology
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– VD/VDR
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
